Clinical Trial to Evaluate ANT-1403 in the Treatment of Primary Axillary Hyperhidrosis

Clinical Trial to Evaluate ANT-1403 in the Treatment of Primary Axillary Hyperhidrosis in Adults

The purpose of this study is to confirm the effect of ANT-1403 in the treatment of primary axillary hyperhidrosis.

Inclusion Criteria:

• ages 18 - 70 years of age
• diagnosis of moderate to severe primary axillary hyperhidrosis
• ≥50 mg of sweat production/axilla in 5 minutes as measured gravimetrically
• HDSS score of ≥3

Exclusion Criteria:

• diagnosis of secondary hyperhidrosis
• skin affliction in the axilla requiring medical treatment
• 20% aluminum hydrochloride, e.g. Drysol®, in 2 weeks prior of Baseline
• oral anticholinergic treatment
• botulinum toxin treatment in the prior 9 months
• history of surgery for axillary hyperhidrosis
• present or history of neuromuscular disease
• female subjects who are pregnant or are nursing a child